What does the future of microfluidics look like in research?
Can you introduce yourself and tell us about your role at Fluigent?
After an engineering degree, a doctorate. in chemical engineering, and 15 years in an innovative international group, I became CEO of Fluigent in 2015.
I focus on building and implementing a successful and ambitious strategy, based on disruptive innovations and high-end products as well as customer satisfaction to meet the needs of the research market and conquer the market. industrial.
Fluigent helps develop advanced fluid control systems for microfluidics. Can you tell us more about Fluigent and some of your goals and missions?
Microfluidics brings a revolution to industry comparable to the invention of microprocessors in information processing. Its potential for research and industry is immense, in particular thanks to the capacities of miniaturization, automation, high throughput which allow the generation of results, for example the performance of analyzes (NGS, DNA, detection of pathogens). It also decreases the consumption of samples and reagents, reduces the duration of experiments and reduces the overall costs of experiments.
It is considered an essential tool for research in life sciences, or more broadly in biotechnology, both for academic researchers and for industrial groups. For example, it allows:
- The development of new personalized therapeutic treatments
- Accelerating the discovery of new drugs and vaccines by reducing time and costs
- The reproduction of a living human organ on a microscopic scale
- Reducing animal testing by testing new drugs on in vitro models (organs on chips)
- Low environmental impact
One key success factor for these applications is the precise control of fluids flowing through the chips. Traditional syringes or peristaltic pumps are struggling to deliver the right level of performance. As a result, there was a need for faster, more stable, and precise technology for fluid handling at the microscale.
Fluigent was the first company to solve this problem by introducing an innovative technology; pressure pumps. Fluigent’s unique broad range of solutions for use in microfluidics and nanofluidics applications ensures full control of flow rates with greater control, automation, precision, ease of use, and no contamination. Fluigent has delivered thousands of patented pressure-based flow controllers systems to hundreds of customers worldwide.
A research lab can use Fluigent’s ready-to-go instruments for a broad range of applications where fluid control is critical. Industrial companies are able to integrate Fluigent’s technology to enhance and improve their own products also.
Our aim is to improve everyday life, and save lives by accelerating tomorrow’s discoveries, their time to market, and their impact on society.
Image Credit: Sergey Nivens/Shutterstock.com
Microfluidics has a wide variety of applications within the life sciences industry including cell biology, particle analysis, and biosensors. How are your instruments and solutions able to adapt to the different sectors?
Our instruments are versatile and can be used for a wide variety of applications where fluid control is critical, thanks to;
- Fluigent’s pressure controllers are not in contact with liquids and thus enable sterility.
- Fluigent’s expertise as an internal control algorithm is able to adapt and provide high-performance control to a variety of fluids, fluid paths and applications.
- An easy-to-use, high-performance software solution to monitor, control all Fluigent devices from a single user interface or develop custom software applications. The software expands instrument capabilities and access to features such as automation and data logging.
- Fluigent instruments are designed and engineered to be easy to use, quickly handled by a variety of scientists, biologists and engineers.
You currently offer a wide variety of smart microfluidic instruments for research. Can you tell us more about some of your products and what advantages they have compared to other microfluidics instruments available?
Our offer covers a wide variety of fluid handling solutions for research and industries. Our core products are pressure-based pumps, they are used with control devices (valves, switches) and measurement devices (pressure, flow, flow rate sensors), as well as software which together constitutes a platform from which any microfluidic experiment can be performed.
Compared to syringe and peristaltic pumps, pressure-based pumps allow for more stable, faster, contact-free, and precise control of the fluids.
To illustrate, I will use the example of micrometer droplets and particles – widely used in a broad range of industries, such as digital PCR and single-cell encapsulation.
Droplet production using microfluidic systems was implemented for applications where monodispersity is of high importance. The droplet size being proportional to the flow rate, a stable flow rate is critical for having repeatable reactor volume and reproducible results. Syringe pumps are commonly used for generating droplets in microfluidic experiments but can show limited flow control. As a consequence, the droplet size is affected.
As an alternative to syringe pumps, pressure-based flow controllers enable highly stable flows, generating highly mono-disperse droplets, enabling better control and reproducibility of results.
Image Credit: Fluigent
On your website, you state that your ‘microfluidic technologies allow you to focus on the science, not on the setup’. Why is this so important for innovation?
Scientists or industrials must focus on where they will bring their highest value: discoveries, new applications, new devices, etc.
At the beginning of Fluigent, 15 years ago, we were facing scientists who were developing and assembling their own fluid control devices. For example, a Ph.D. student will spend 6 months building their own device before starting their biological experiments. I believe these 6 months were lost to just end up with a piece of average equipment. The student will then only have the rest of their time to help the science progress.
Our value proposition is to offer ready-to-use, high-end products so that users can focus on what matters! By enabling scientists to focus on science we believe that we accelerate innovation and discoveries. By enabling engineers to work on the development of new tools for diagnostics, therapeutics, new devices – we believe that we are accelerating their time to market and their impact on society.
The life sciences industry has seen tremendous breakthroughs in recent years due to advances in technology and artificial intelligence (AI). What role does technology play in new discoveries? Do you see the role of technology within research becoming more prominent in years to come?
For me, technology plays an essential role in new discoveries by giving new tools, new possibilities to go beyond the limits, the way of thinking. I will illustrate with an example from one of our customers.
He compared the traditional robotic method to the droplet microfluidic method to perform ultra-high-throughput screening of an enzyme. For the same number of reactions (50 million), he was able to decrease the time needed from 2 years with a robot to 7 hours using microfluidics. I think that this is a good example of how technology can be a strong game-changer.
Technology is also improving patient care with new treatments, new diagnostics tools (medical imaging, Point of Care or Point of Need diagnostics), and new tools for surgeons (robots).
An interesting example is MRI as it was primarily used as a tool for researchers and scientists and has been very well adopted by doctors to perform daily exams. That’s a great example of lab technology which is now part of the routine at the hospital!
Despite these breakthroughs, there are still many challenges that need to be overcome when adopting new technology in research. What do you believe to be some of the biggest challenges currently faced by the life sciences industry and how can we overcome them?
I will give a few examples, which are close to our applications. The path from traditional drugs to immunotherapies, using the immune system to fight against some diseases remain a challenge.
Personalized medicine is another example, with several directions to explore:
- Understanding and correlating the characteristics of an individual – determined by their genetics, epigenetics and individual specificity – to therapies, thanks to computer science and AI. This should lead to either new treatments/drugs or dedicated treatment
- Develop methods and instruments to test different therapies on THE patient’s cancer. Here, microfluidics can help with miniaturized and automated solutions.
It is also difficult to reduce the quantities of cells or blood collected for diagnostic purposes or to develop targeted therapies.
The controlled release of a drug after ingestion could be another example. When you take a drug today, the dose is usually higher because the immune system suppresses some of it; it is too high at first and then too low. Again, microfluidics can help overcome this problem by encapsulating the IPA and thus allowing a smooth and gradual diffusion of the drug in our body.
Image Credit: irinabdw/Shutterstock.com
Looking to the future, are there any particular sectors within the life sciences industry that people should pay particular attention to?
There are many new technologies being evaluated or developed today. I believe that organ-on-chip and spheroid cultures, which are able to mimic living human organs, could be a game-changer in the development and screening of new drugs.
Indeed, this is one of the unpleasant truths of clinical studies: even after the most painstaking preclinical studies in rodents, 80% of drugs are not effective in humans. However, a series of such studies can cost millions of dollars.
These new technologies allow scientists to develop models of human organs by culturing cells under conditions close to the physiological environment, which makes it possible to evaluate and predict the human response according to the objective of the study: it could be in vitro drug, toxin and therapy testing, for example.
The main advantages are the shortened development time, the removal of the species barrier, the reduction in the number of animals used for the tests, hence a reduction in the costs of this long development.
What’s next for Fluigent? Are there any exciting upcoming projects you are involved in?
We have several disruptive technologies in the pipeline that will allow us to unlock some of the real limits of microfluidics (eg pushing the boundaries of miniaturization, connectivity, measurements or data, etc.).
This summer we will launch OMI, a portable, connected, pocket organ on a chip platform to imitate living organs. the in vitro the models enabled by OMI bring significant advances in the understanding of aging, in the ability to personalize treatments in record time, in drug development and in the study of infectious diseases. Experiments are simplified, automated and more reliable – while dramatically reducing animal experiments
Where can readers find more information?
About France Hamber
After an engineering degree and a doctorate. in chemical engineering, I joined the Air Liquide group where I held management positions in fields with high technological and innovation intensity and I had the opportunity to bring products from R&D to industrial production.
I became CEO of Fluigent in 2015 and I focus on building and implementing a successful and ambitious strategy, based on disruptive innovations and high-end products as well as customer satisfaction to meet the needs of the research market and conquer the industrial market.